Society guideline links: Management of toxicities due to checkpoint inhibitor immunotherapy

Introduction — This topic includes links to society and government-sponsored guidelines from selected countries and regions around the world. We will update these links periodically; newer versions of some guidelines may be available on each society's website. Some societies may require users to log in to access their guidelines.

The recommendations in the following guidelines may vary from those that appear in UpToDate topic reviews. Readers who are looking for UpToDate topic reviews should use the UpToDate search box to find the relevant content.

Links to related guidelines are provided separately. (See "Society guideline links: Cancer pain".)

International

●Society for Immunotherapy of Cancer (SITC): Clinical practice guideline on immune checkpoint inhibitor-related adverse events (2021)

●Multinational Association of Supportive Care in Cancer (MASCC): Clinical practice recommendations for the management of immune checkpoint inhibitor endocrinopathies and the role of advanced practice providers in the management of immune-mediated toxicities (2020)

●MASCC: Clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors (2020)

●MASCC: Clinical practice recommendations for the management of immune-related adverse events – Pulmonary toxicity (2020)

●MASCC: Clinical practice recommendations for the management of severe dermatological toxicities from checkpoint inhibitors (2020)

●MASCC: Clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors (2020)

●MASCC: Recommendations for the management of immune-related adverse events of patients undergoing treatment with immune checkpoint inhibitors (2020)

Canada

●Cancer Care Ontario (CCO): Clinical practice guideline for immune checkpoint inhibitor toxicity management (2018)

United States

●American Society of Clinical Oncology (ASCO): Guideline for management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy, update (2021)

Europe

●European Society of Medical Oncology (ESMO): Management of toxicities from immunotherapy – Clinical practice guideline for diagnosis, treatment, and follow-up (2022)

●European Alliance of Associations for Rheumatology (EULAR): Recommendations – Points to consider for the diagnosis and management of rheumatic immune-related adverse events due to cancer immunotherapy with checkpoint inhibitors (2021)

Japan

●Japan Endocrine Society (JES): Clinical guidelines for management of immune-related adverse events in endocrine organs induced by immune checkpoint inhibitors (2019)